Immune checkpoint inhibitors (ICIs) have redefined cancer therapy by blocking pathways such as PD-1/PD-L1 and CTLA-4, thereby restoring antitumor immunity and altering the tumor microenvironment (TME) [8,9,10]. Here, PDCD1 is linked to cancer.